COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 2350: Articles 23491-23500  | Next

Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development
Gruca, A., Ziemska-Legiecka, J., Jarnot, P., Sarnowska, E., Sarnowski, T., Grynberg, M.
10.1101/2020.08.11.245993 — Posted: 2020-08-11
K18-hACE2 mice develop respiratory disease resembling severe COVID-19
Yinda, C. K., Port, J. R., Bushmaker, T. J., Offei Owusu, I., Avanzato, V. A., Fischer, R. J., Schulz, J. E., Holbrook, M. G., Hebner, M. J., Rosenke, R., Thomas, T., Marzi, A., Best, S. M., de Wit, E., Shaia, C., van Doremalen, N., Munster, V.
10.1101/2020.08.11.246314 — Posted: 2020-08-11
Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
Timmins, G. S., Bradfute, S. B., Deretic, V., Kumar, S., Clarke, E. C., Ye, C.
10.1101/2020.08.11.245100 — Posted: 2020-08-11
Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: in vivo, in silico and in vitro preliminary evidences
Campione, E., Lanna, C., Cosio, T., Rosa, L., Conte, M. P., Iacovelli, F., Romeo, A., Falconi, M., Del Vecchio, C., Franchin, E., Lia, M. S., Minieri, M., Chiaramonte, C., Ciotti, M., Nuccetelli, M., Terrinoni, A., Iannuzzi, I., Coppeda, L., Magrini, A., Moricca, N., Sabatini, S., Rosapepe, F., Bartoletti, P. L., Bernardini, S., Andreoni, M., Valenti, P., Bianchi, L.
10.1101/2020.08.11.244996 — Posted: 2020-08-11 Discussion: Onsite | Offsite
Post-exertion oxygen saturation as a prognostic factor for adverse outcome in patients attending the emergency department with suspected COVID-19: Observational cohort study
Goodacre, S., Thomas, B., Lee, E., Sutton, L., Biggs, K., Marincowitz, C., Loban, A., Waterhouse, S., Simmonds, R., Schutter, J., Connelly, S., Sheldon, E., Hall, J., Young, E., Bentley, A., Challen, K., Fitzsimmons, C., Harris, T., Lecky, F., Lee, A., Maconochie, I., Walter, D.
10.1101/2020.08.10.20171033 — Posted: 2020-08-11
Mass molecular testing for COVID19 using NGS-based technology and a highly scalable workflow
Malta, F. d. M., Amgarten, D. E., Val, F. C., Santana, R. A. F., Cervato, M. C., de Azevedo, B. M. C., Basqueira, M. d. S., Alves, C. O. d. S., Nobrega, M. S., Rebello Pinho, J. R.
10.1101/2020.08.10.20172106 — Posted: 2020-08-11
The selection of reference genome and the search for the origin of SARS-CoV-2
Liu, Y., Yan, C.
10.1101/2020.08.10.245290 — Posted: 2020-08-11 Discussion: Onsite
AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic
Good, S. S., Westover, J., Jung, K. H., La Colla, P., Collu, G., Moussa, A., Canard, B., Sommadossi, J.-P.
10.1101/2020.08.11.242834 — Posted: 2020-08-11
Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis
Gu, H., Yuan, G.
10.1101/2020.08.09.243444 — Posted: 2020-08-11
A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions
Fu, Y., Pistolozzi, M., Yang, X., Lin, Z.
10.1101/2020.08.11.232520 — Posted: 2020-08-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).